Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

K Shitara; E Van Cutsem; YJ Bang; CS Fuchs; L Wyrwicz; KW Lee; I Kudaba; M Garrido; HC Chung; HR Castro; W Mansoor; MIFM Braghiroli; E Goekkurt; J Chao; ZA Wainberg; U Kher; S Shah; SP Kang; J Tabernero

Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

K Shitara, E Van Cutsem, YJ Bang, CS Fuchs, L Wyrwicz, KW Lee, I Kudaba, M Garrido, HC Chung, HR Castro, W Mansoor, MIFM Braghiroli, E Goekkurt, J Chao, ZA Wainberg, U Kher, S Shah, SP Kang, J Tabernero

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	LBA44
Pages (from-to)	878
Journal	Annals of Oncology
Volume	30
Issue number	Suppl.5
Publication status	Published - Oct 2019
Externally published	Yes
Event	European Society of Medical Oncology (ESMO) Congress - Barcelona, Spain Duration: 27 Sept 2019 → 1 Oct 2019 Conference number: 44 https://www.esmo.org/meetings/past-meetings/esmo-congress-2019

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Shitara, K., Van Cutsem, E., Bang, YJ., Fuchs, CS., Wyrwicz, L., Lee, KW., Kudaba, I., Garrido, M., Chung, HC., Castro, HR., Mansoor, W., Braghiroli, MIFM., Goekkurt, E., Chao, J., Wainberg, ZA., Kher, U., Shah, S., Kang, SP., & Tabernero, J. (2019). Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062. Annals of Oncology, 30(Suppl.5), 878. Article LBA44. https://doi.org/10.1093/annonc/mdz394.035

@article{cdcde6a370c74ffca6d11e0d70eb5720,

title = "Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062",

author = "K Shitara and {Van Cutsem}, E and YJ Bang and CS Fuchs and L Wyrwicz and KW Lee and I Kudaba and M Garrido and HC Chung and HR Castro and W Mansoor and MIFM Braghiroli and E Goekkurt and J Chao and ZA Wainberg and U Kher and S Shah and SP Kang and J Tabernero",

year = "2019",

month = oct,

language = "English",

volume = "30",

pages = "878",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "Suppl.5",

note = "European Society of Medical Oncology (ESMO) Congress, ESMO 2019 ; Conference date: 27-09-2019 Through 01-10-2019",

url = "https://www.esmo.org/meetings/past-meetings/esmo-congress-2019",

}

Shitara, K, Van Cutsem, E, Bang, YJ, Fuchs, CS, Wyrwicz, L, Lee, KW, Kudaba, I, Garrido, M, Chung, HC, Castro, HR, Mansoor, W, Braghiroli, MIFM, Goekkurt, E, Chao, J, Wainberg, ZA, Kher, U, Shah, S, Kang, SP & Tabernero, J 2019, 'Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062', Annals of Oncology, vol. 30, no. Suppl.5, LBA44, pp. 878. <https://doi.org/10.1093/annonc/mdz394.035>

Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062. / Shitara, K; Van Cutsem, E; Bang, YJ et al.
In: Annals of Oncology, Vol. 30, No. Suppl.5, LBA44, 10.2019, p. 878.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

AU - Shitara, K

AU - Van Cutsem, E

AU - Bang, YJ

AU - Fuchs, CS

AU - Wyrwicz, L

AU - Lee, KW

AU - Kudaba, I

AU - Garrido, M

AU - Chung, HC

AU - Castro, HR

AU - Mansoor, W

AU - Braghiroli, MIFM

AU - Goekkurt, E

AU - Chao, J

AU - Wainberg, ZA

AU - Kher, U

AU - Shah, S

AU - Kang, SP

AU - Tabernero, J

N1 - Conference code: 44

PY - 2019/10

Y1 - 2019/10

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000491295500168

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

SP - 878

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.5

M1 - LBA44

T2 - European Society of Medical Oncology (ESMO) Congress

Y2 - 27 September 2019 through 1 October 2019

ER -

Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this